Paediatric Inflammatory Bowel Disease: A Multi-Stakeholder Perspective to Improve Development of Drugs for Children and Adolescents.

"Conflict of Interest AMG: Consultant to Abbvie, Amgen, BristolMyersSquibb, Janssen, Lilly, Merck, Pfizer. Speaker fees from Abbvie, Janssen, Nestle. Investigator-initiated research support from Abbvie. CP: Is an employee of the European Medicines Agency. FMR: Collaboration [advisory boards, consulting, scientific presentations] with Schering-Plough, Ferring, MSD, Johnson & Johnson, Centocor, AbbVie; Nestlé Nutrition Institute, Nestlé Health Science, Danone, MeadJohnson, Takeda, Celgene, Biogen, Bristol Myers Squibb, Gossamer, Lilly. DT: during last 3 years, has received consultation fee, research grant, royalties or honorarium from Janssen, Pfizer, Hospital for Sick Children, Ferring, AbbVie, Takeda, Atlantic Health, Shire, Celgene, Lilly, Roche, ThermoFisher, Bristol-Meyers Squibb. GV: Provided advice on paediatric oncology drug development to Astra-Zeneca, Bayer, Bristol Meyers Squib, Celgene, Hutchinson-Medi Pharma, Ipsen, Celltrion, Merck, Novartis, Pfizer, Roche/Genentech. He does not accept personal remuneration. GV is also is a board member of SIOP Europe [the European Society for Paediatric Oncology]. JSH: Advisory board for Janssen, AbbVie. Consultant to Lilly, Boehringer Ingelheim, Bristol Myers Squibb, Thetis, Takeda, Pfizer. KC: Is an employee of Janssen, UK. KN: Is an employee of the European Medicines Agency. LdR: Collaboration [such as involved in industry-sponsored studies, investigator-initiated study, consultancy] with Celltrion, AbbVie, Eli Lilly, Takeda, Pfizer. AE, FL, IL, MC-B, MG, ZG: None. NMC: Trial funding, advisory board and speakers fees paid to his institution from AbbVie, Eli Lilly, Takeda, Shire, Pfizer, Janssen. RN: Is an employee of Johnson & Johnson. TAA: Is an employee of the US Food and Drugs Administration. WC: Is an employee of Eli Llly and Company. As well as the authors declaration of interests, participants of the 2-day meeting included employees of AbbVie, AstraZeneca, Boehringer Ingelheim, Eli Lilly & Company, GSK, Janssen, Johnson & Johnson, OSE Immunoth, Pfizer, Roche Genentech and Servier."

"Funding This work was supported by the Collaborative Network for European Clinical Trials for Children [conect4children; c4c], including medical writing support, and has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No. 777389. The Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and European Federation of Pharmaceutical Industries and Associations."